Beam Therapeutics Inc.
NASDAQ:BEAMBiotechnology
+$0.48 today
- Market cap
- $2.17B
- Beta
- 2.20
- P/E (TTM)
- -52.3
- EPS (TTM)
- -$0.63
Volume 4.86M
Average 2.11M
BEAM Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Beam Therapeutics Inc.NASDAQ: BEAM
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development dips below year-ago levels
Q2 FY2026 research & development of $95.1M fell 6.5% year over year, behind the +3.1% change in trailing-twelve-month research & development. Sequentially, it fell 9.0% from the prior quarter. Over 3 fiscal years it compounded at +9.5% a year.
Context
- Research & development amounted to 293.1% of revenue in FY2025, down 285.5 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -6.5% toward the trailing-twelve-month pace of +3.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 409.62M USD
- Year-over-year change
- +11.4%
- 4-year CAGR
- +1.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 409.62M | +11.4% |
| FY2024 | 2024-12-31 | 367.56M | -16.0% |
| FY2023 | 2023-12-31 | 437.38M | +40.4% |
| FY2022 | 2022-12-31 | 311.59M | -19.5% |
| FY2021 | 2021-12-31 | 387.09M | — |
Research & Development vs competitors
How BEAM compares with its peers on the latest reported figures
- BEAM's LTM Jun 2026 research & development of $408.66M is the highest of the 9 companies compared; the peer median is $97.58M.
- Its year-over-year change of +3.1% is the 2nd highest of 9, against a peer median of -22.7%.
- Research & development amounts to 261.9% of revenue for BEAM, versus a peer median of 546.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $408.66M | +3.1% | +9.5% | 261.9% | |
| LTM Mar 2026 | $361.17M | -21.5% | -2.5% | 546.5% | |
| LTM Sep 2026 | $283.28M | +1.6% | -16.9% | 1125.4% | |
| LTM Mar 2026 | $129.09M | -32.1% | -16.3% | — | |
| LTM Mar 2026 | $100.48M | -23.9% | -30.4% | 1590.8% | |
| LTM Mar 2026 | $94.68M | +5.0% | -1.4% | 139.0% | |
| LTM Mar 2026 | $94.52M | -28.3% | +10.0% | 843.7% | |
| LTM Mar 2026 | $66.19M | -62.3% | -19.9% | 171.1% | |
| LTM Mar 2026 | $53.36M | -10.8% | +5.5% | 118.4% | |
| Peer median (excluding BEAM) | $97.58M | -22.7% | -9.4% | 546.5% | |
Competitors are the stored peer set for BEAM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 51.84M | 60.92M | 377.71M | 63.52M | 139.74M |
| Cost of Revenue | 232.13M | 311.59M | 0 | 367.56M | 22.29M |
| Gross Profit | (180.29M) | (250.67M) | 377.71M | (304.04M) | 117.45M |
| Gross Margin | -347.8% | -411.5% | 100.0% | -478.7% | 84.0% |
| Research & Development | 387.09M | 311.59M | 437.38M | 367.56M | 409.62M |
| Selling, General & Admin | 57.22M | 87.81M | 116.81M | 111.53M | 113.82M |
| Operating Expenses | 212.18M | 87.81M | 554.19M | 111.53M | 501.14M |
| Depreciation & Amortization | 7.45M | 14.15M | 20.01M | 21.93M | 22.29M |
| EBITDA | (230.06M) | (271.53M) | (111.15M) | (354.78M) | (13.97M) |
| EBITDA Margin | -443.8% | -445.7% | -29.4% | -558.5% | -10.0% |
| Operating Income | (392.47M) | (338.48M) | (176.49M) | (415.57M) | (383.69M) |
| Operating Margin | -757.0% | -555.6% | -46.7% | -654.3% | -274.6% |
| Interest Income | 0 | 15.3M | 46.68M | 49.09M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 43.73M |
| Other Income / Expenses | 21.83M | 52.8M | 45.32M | 38.87M | 303.7M |
| Income Before Tax | (370.64M) | (285.68M) | (131.16M) | (376.7M) | (79.99M) |
| Pre-Tax Margin | -714.9% | -468.9% | -34.7% | -593.1% | -57.2% |
| Income Tax Expense | 0 | 3.41M | 1.37M | 39K | 0 |
| Net Income | (370.64M) | (289.09M) | (132.53M) | (376.74M) | (79.99M) |
| Net Margin | -714.9% | -474.5% | -35.1% | -593.1% | -57.2% |
| EPS (Basic) | (5.77) | (4.13) | (1.72) | (4.58) | (0.81) |
| EPS (Diluted) | (5.77) | (4.13) | (1.72) | (4.58) | (0.81) |
| Weighted Avg Shares | 64.23M | 70.02M | 77.15M | 82.31M | 98.91M |
| Weighted Avg Shares (Diluted) | 64.23M | 70.02M | 77.15M | 82.31M | 98.91M |
Beam Therapeutics Inc.
NASDAQ:BEAM
Intrinsic Alpha fair value
Locked
Current Price
$21.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.